A Proof-of-Activity Study With Orticumab in Subjects With Psoriasis and Cardiometabolic Risk Factors

Inclusion criteria: * Stable/chronic plaque psoriasis with PASI score of ≥ 12 AND involving ≥ 10% of the subject's BSA.- ≥ 30 years of age at time of consent. * BMI ≥ 30 kg/m2 * LDL ≥ 100 mg/dL at Screening. * All females must have a negative serum pregnancy test result at Screening and a negative urine pregnancy test prior to dosing. Exclusion Criteria: Subjects are excluded from the study if any of the following criteria are met: * Past use of orticumab. * Any of the nonplaque forms of psoriasis: erythrodermic, guttate, or pustular. * Scalp, palmar or plantar psoriasis only, at Screening or Baseline. * Have evidence of skin conditions (e.g., eczema) at the time of Screening or Baseline visit that would interfere with theevaluation of psoriasis. * Newly discovered Type 2 diabetes mellitus (T2DM) * Moderate or high-intensity statin use or new use of a low-intensity statin therapy. * No use of anti-coagulating or anti-thrombotic agents. * Poorly controlled hypertension * Use of an IL-23 blocker in the past 180 days, an IL-17 blocker in the past 16 weeks, or a TNF blocker in the past 12 weeks. * Use of methotrexate, cyclosporine, or apremilast in the past 4 weeks. * History of hypersensitivity or allergies to any contents in the orticumab formulation. * A history of any clinically important abnormalities in cardiac rhythm or conduction. * A history of prolonged QT intervals or a family history of long QT-syndrome at Screening. * A history of first, second or third-degree atrioventricular (AV) block, or AV dissociation. * A history of complete bundle branch block. * Unstable angina pectoris, myocardial infarction, transient ischemic attack, or stroke within 3 months prior to Screening, or participants who have undergone percutaneous coronary intervention or a coronary artery bypass graft within 6 months prior to Screening or who are due to undergo these procedures at the time of Screening. * Severe congestive heart failure (NYHA III or IV).